MGMT and glioblastoma: For instance, in a Phase-II trial, patients with GBM who have an unmethylated MGMT promoter administered with single dose of autologous CD34+-enriched HSPCs exposed to transduction with a 3rd generation LV driving myeloid-specific IFN-α2 expression (NCT03866109) (Table 3).